Multimodal Brain Imaging of Methylphenidate in Children and Adolescents With ADHD
Status:
Withdrawn
Trial end date:
2029-01-01
Target enrollment:
Participant gender:
Summary
The goal of this proposal is to develop brain imaging tools to measure the effects of
methylphenidate in children and adolescents with attention deficit hyperactivity disorder
(ADHD). Methylphenidate is an FDA-approved treatment for ADHD. Specifically, the
investigators will correlate brain activity during cognitive tasks and brain chemistry with
cognitive performance. These measures could help the investigators understand how current
ADHD medications work and then could be used to develop novel drugs to treat ADHD in children
and adolescents.